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Despite the fact that harboring the apolipoprotein E4 (APOE4) allele represents the single greatest risk factor for late-onset 
Alzheimer’s disease (AD), the exact mechanism by which apoE4 contributes to disease progression remains unknown. Recently, 
we demonstrated that a 151 amino-terminal fragment of apoE4 (nApoE41-151) localizes within the nucleus of microglia in the 
human AD brain, suggesting a potential role in gene expression. In the present study, we investigated this possibility utilizing 
BV2 microglia cells treated exogenously with nApoE41-151. The results indicated that nApoE41-151 leads to morphological 
activation of microglia cells through, at least in part, the downregulation of a novel ER-associated protein, CXorf56. Moreover, 
treatment of BV2 cells with nApoE41-151 resulted in a 68-fold increase in the expression of the inflammatory cytokine, TNFα, a  
key trigger of microglia activation. In this regard, we also observed a specific binding interaction of nApoE41-151 with the TNFα 
promoter region. Collectively, these data identify a novel gene-regulatory pathway involving CXorf56 that may link apoE4 to 
microglia activation and inflammation associated with AD. 
1. Introduction 
Alzheimer’s disease (AD) currently has a significant global 
impact. In the USA alone, over 5.7 million Americans suffer 
from this progressive, irreversible brain disorder that 
destroys memory and thinking skills [1]. A central tenet 
underlying AD is chronic inflammation that may contribute 
to the underlying pathology and neurodegeneration. Evi­
dence documented for the past 30 years has proven the exis­
tence of inflammation in AD, including activated microglia 
within and surrounding senile plaques [2–5]. Despite this 
wealth of evidence, the stimuli that led to microglia activation 
and subsequent inflammation in AD are not well described. 
One possible connection linking these two events may be 
the apoE4 protein. The APOE4 allele represents the single 
greatest risk factor for late-onset AD, and inheritance of 
one copy of the APOE4 allele increases Alzheimer’s disease 
(AD) risk fourfold, while two copies raises the risk tenfold 
[6]. A recent study linking apoE4 to neuroinflammation in 
AD demonstrated that apoE4-expressing microglia exhibit 
higher innate immune reactivity after lipopolysaccharide 
treatment and this in turn may promote neuroinflammation 
in AD [7]. 
We recently documented the presence of an amino-
terminal fragment of apoE4 1-151 (nApoE41-151) within the 
nucleus of microglia cells in the human AD brain [8]. In 
vitro, exogenous treatment of BV2 microglial cells with 
nApoE41-151 led to uptake and trafficking to the nucleus 
[8]. In the present study, we sought to examine the functional 
consequences of nuclear localization of nApoE41-151 with a 
working hypothesis that this fragment acts as a transcription 
factor leading to gene expression changes within microglia. 
Our results indicated that nApoE41-151 does regulate the 
expression of several genes including a novel, previously 
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uncharacterized gene, CXorf56. These findings have potential 
broad implications implicating apoE4 to dementia risk per­
haps through microglia activation and enhanced inflamma­
tion in the AD brain. 
2. Materials and Methods 
2.1. Materials. The anti-CXorf56 rabbit polyclonal antibody 
was purchased from Thermo Fisher Scientific (Rockford, 
IL). Besides human CXorf56, this antibody has the highest 
antigen sequence identity to mouse (100%) and rat (100%) 
CXorf56. The mouse monoclonal anti-calnexin antibody 
was purchased from Abcam Inc. (Cambridge, MA). Mito-
Tracker Deep Red FM was purchased from Thermo Fisher 
Scientific (Rockford, IL). Construction and purification of 
the amino-terminal fragment 1-151 for apoE4 (nApoE41­
151) were contracted out to GenScript (Piscataway, NJ). The 
anti-beta-actin monoclonal antibody was purchased from 
ABclonal (Woburn, MA). 
2.2. Cell Culture of BV2 Cells. BV2, murine microglial 
cells, were maintained at 37 ° C and 6% CO2 in a humidi­
fied incubator. Cells were maintained in RPMI 1640 media 
(HyClone) supplemented with 10% standard fetal bovine 
serum (HyClone), 10% Cellgro MEM Nonessential Amino 
Acid (Corning), and 10% penicillin-streptomycin (HyClone). 
Cells were cultured in 50 ml T25 flasks. For experimentation, 
cells were grown on BioCoat poly-D-lysine glass multiwell 
culture slides (Corning). All supplies were purchased from 
Thermo Fisher Scientific Inc. (Waltham, MA). Treatment of 
BV2 cells was undertaken by incubation with nApoE41-151 
25 μg/ml for either 5 hours to assess mRNA expression or 24 
hours prior to immunocytochemical or Western blot studies. 
2.3. Chromatin Immunoprecipitation (ChIP-seq). Chromatin 
immunoprecipitation (ChIP-seq) was employed to deter­
mine what DNA sequences the nApoE41-151 fragment may 
be binding to directly following treatment of BV2 cells. 
ChIP-seq was performed according to the manufacturer’s 
instructions (Abcam’s high-sensitivity ChIP kit (product num­
ber: ab185913). nApoE41-151 pulled-down DNA sequences 
were then outsourced (DNA Integrated Technologies) to be 
sequenced. Numerous controls were included including a 
positive control antibody (RNA polymerase II), a negative 
control nonimmune IgG, and GAPDH primers to demon­
strate the efficacy of the kit reagents and protocol. 
2.4. CXorf56 and TNFα Quantitative PCR. Primers were 
designed to specifically amplify a portion of either the 
CXorf56 or TNFα genes. Serine/arginine-rich splicing factor 
11 (SFRS11) and EH domain-binding protein 1 (EHBP), two 
ultraconserved elements that have invariant copy number in 
mice, were used as reference genes. All primers were synthe­
sized by Integrated DNA Technologies (Coralville, IA). For 
TNFα, the forward sequence was ACGGCATGGATCTC 
AAAGAC and the reverse was AGATAGCAAATCGGCT 
GACG [9]. Primer efficiencies (E%) were confirmed to be 
between 90 and 110%. Primers were confirmed to be specific 
based upon melting profiles (Table 1). 
Table 1 
Gene Oligo sequences (5′ -3′ ) E% 
SFRS11 
AAATACCACCCAACAGTTT 
AAGCCCTATACAGATGGAT 
101 
EHBP 
GAGTCTCCAATATCATCAGTAAGC 
ACACATGCCACGATCAATG 
96 
CXorf56 
GTGTTGCCAGGAAATAGTTTTCTTC 
CCCAGGATCGCTAAC 
109 
The total volume for each reaction was 20 μl and included 
10 μl Fast EvaGreen qPCR Master Mix (Biotium Inc., Ca, 
USA), 1 μl of each appropriate primer (10 μM), 4 μl of water, 
and 4 μl of template cDNA. Each PCR reaction also included 
a reverse transcription negative control to confirm the 
absence of genomic DNA in triplicate and a nontemplate 
negative control to confirm the absence of primer dimeriza­
tion in triplicate. Real-time qPCR was run on a LightCycler 
96 (Roche, Basel, Switzerland). The cycling conditions were 
1 cycle of denaturation at 95 ° C for 3 min, followed by 40 
cycles of amplification (95 ° C for 30 sec, 55 ° C for 30 sec, 
and 68 ° C for 30 sec) and one cycle of product melting 
(95 ° C for 10 sec, 65 ° C for 60 sec, and 97 ° C for 1 sec). All sam­
ples were amplified in triplicate, and the Cq value for each 
reaction was determined by the LightCycler 96 SW1.1. Rela­
tive differences in expression between treatments were deter­
mined by the LightCycler 96 SW1.1 and confirmed with the 
ΔΔCt method. 
2.5. Double-Stranded Small Interfering RNA Synthesis and 
Transfection. Double-stranded small interfering RNAs (siR-
NAs) were synthesized by Integrated DNA Technologies 
(Coralville, IA). Two different siRNAs were synthesized to 
target CXorf56 mRNA and termed siRNA(2) and siRNA(3), 
respectively. A third control siRNA was designed as a nega­
tive control and consisted of a scrambled sequence. BV2 
microglia cells were approximately 60% confluent prior to 
transfection. Transfection was achieved by combining 25 μl 
of Opti-MEM Reduced Serum Media (Thermo Fisher Scien­
tific), 0.75 μl of Lipofectamine RNAiMAX Transfection 
Reagent (Thermo Fisher Scientific), and 1.25 pmol of the 
appropriate siRNA and pipetting the mixture directly onto 
the plated cells in 48-well plates. A TYE 563-labeled siRNA 
was used as a positive transfection control, a HPRT-s1 siRNA 
was used as an endogenous gene positive control, and a 
scrambled siRNA was used as a negative control. Treatments 
were for 5 hours to assess CXorf56 mRNA downregulation or 
24 hours to assess protein levels. 
2.6. Total RNA Extraction and cDNA Synthesis. Total RNA 
was extracted from cells with the Direct-zol RNA MicroPrep 
Kit (Zymo Research Corp., CA, USA) according to manufac­
turer’s instructions. Genomic DNA was eliminated using 
TURBO DNAse as described by the manufacturer (Life 
Technologies, CA). RNA quality was assessed using spectro­
photometry and gel electrophoresis. Total cDNA was gener­
ated from 1 μg of total RNA using qScript cDNA SuperMix 
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(QuantaBio, MA, USA). Prior to use in qPCR, cDNA was 
diluted 1 : 2 with water. 
2.7. Confocal Microscopy. Following treatment studies, BV2 
cells were fixed by incubating cells in 4% paraformaldehyde 
for 23 minutes. For antibody labeling, cells were washed with 
0.1 M Tris-buffered saline (TBS), pH 7.4, and pretreated with 
3% hydrogen peroxide in 10% methanol to block endogenous 
peroxidase activity. Slides were subsequently washed in TBS 
with 0.1% Triton X-100 (TBS-A) and then blocked for thirty 
minutes in TBS-A with 3% bovine serum albumin (TBS-B). 
Slides were further incubated overnight at room tempera­
ture with the anti-His rabbit antibody (1 : 2,000). Following 
two washes with TBS-A and a wash in TBS-B, slides were 
incubated with the anti-rabbit HRP-conjugated secondary 
antibody. Visualization was accomplished by using a tyra­
mide signal amplification kit (Molecular Probes, Eugene, 
OR) consisting of Alexa Fluor 488-labeled tyramide (green, 
Ex/Em = 495/519). Slides were mounted using ProLong Gold 
Antifade Mountant with DAPI (Molecular Probes). 
2.8. Microsome Isolation and Western Blot Analysis. ER-
enriched fractions from BV2 microglia cells were prepared 
using a microsome isolation kit (BioVision, Milpitas, CA) 
according to the manufacturer’s instructions. Western blot 
analysis was performed as previously described [10]. Pro­
teins were separated by 15% SDS-PAGE and transferred to 
nitrocellulose. Transferred slabs were stained in Coomassie 
blue to verify equal loading between samples. Membranes 
were incubated in a CXorf56 antibody (1 : 500) or a calnexin 
antibody (1 : 100) overnight at 4 ° C, and primary antibodies 
were visualized using the goat anti-rabbit HRP-linked sec­
ondary antibody, incubated for 1 hour at room temperature 
(1 : 5,000) (Jackson’s Laboratory, West Grove, PA), followed 
by ECL detection. To confirm equal protein loading, Western 
blot analysis was also carried out using a beta-actin antibody 
at 1 : 50,000). Densitometry analysis was performed using the 
Image Studio software, version 5.2.5 (LI-COR Biosciences). 
2.9. Quantification of Morphological Changes and Statistical 
Analysis. NeuronJ is distributed as a plugin for ImageJ, free 
image analysis software distributed by the National Institutes 
of Health. Semiautomated tracing with NeuronJ has been 
shown to be as accurate as both fully manual [11] and fully 
automated tracing [12]. BV2 microglia cells were treated as 
described above with siRNAs for 24 hours. Following treat­
ments, two-dimensional 20x images were obtained using 
bright-field microscopy. Images from each well were taken 
in a random location and converted to the proper format 
for use with the NeuronJ software. Following conversion, 
the number of cells and number of pseudopods in each image 
were manually counted. To assess the length of the pseudo-
pods, the neuron tracing feature of NeuronJ was employed. 
After pseudopods were traced, a text file containing measure­
ments of the lengths of all the pseudopods was exported to 
Excel for analysis. Statistical differences in this study were 
determined using Student’s two-tailed t-test employing 
Microsoft Office Excel. 
2.10. DNA Mobility Shift Assays. The binding reactions were 
created by combining 2 μl of 10x binding buffer (Thermo Sci­
entific Cat. #20148), 1 μl of 50% glycerol, 1 μl of 100 mM 
MgCl2, 1  μl of 1  μg/μl poly(dI · dC), 1 μl of 1% NP-40, and 
20 fmol of TNFα promoter region DNA. The murine TNFα 
promoter region DNA was synthesized and biotinylated at 
the 5′ end by Integrated DNA Technologies Inc. utilizing 
the following sequence: ATGCTTGTGTGTCCCCAACTT 
TCCAAATCCCCGCCCCCGCGATGGAGAAGAAACCG 
AGACAGAAGGTGCAGGGCCCACTACCGCTTCCTCC 
AGATGAGCTCATGGGTTTCTCCACCAAGGAAGTTT 
TCCGCTGGTTGAATGATTCTTTCCCCGCCCTCCTCT 
CGCCCCAGGGACATATAAAG GCAGTTGTTGGCAC 
ACCA. Finally, either 3.6 μg of nApoE41-151 protein frag­
ment or 3.6 μg of full-length ApoE4 protein was added with 
the addition of nuclease-free water to each reaction to bring 
the final volume to 20 μl. All reactions were incubated at 
room temperature for twenty minutes. 
Following preincubation of DNA with protein, a 5% TBE 
precast polyacrylamide gel (Bio-Rad Cat. #4565013) was pre­
pared with 0.5x TBE as the loading buffer. The gel was pre­
electrophoresed at 100 V for 30 minutes. 5 μl of 5x loading 
buffer (Thermo Scientific Cat. #20148) was mixed into each 
reaction; 20 μl of each mixture was loaded, and reactions 
were separated at 100 V. Following separation, reactions 
were transferred at 100 V for 30 minutes onto a Biodyne™ 
B Precut Modified Nylon Membrane, 0.45 μm (Thermo Sci­
entific Cat. #77016). Following the transfer, the DNA on the 
membrane was cross-linked at a distance of approximately 
0.5 cm from the membrane for 5 minutes with a 254 nm 
handheld UV lamp. The Biotin-labeled DNA was detected 
using the Chemiluminescent Nucleic Acid Detection Mod­
ule (Thermo Scientific Cat. #89880) according to the manu­
facturer’s instructions. 
2.11. Cytokine ELISA Assays. To quantify the levels of 
secreted TNF-alpha or IL-1beta in BV2 cells, mouse TNF-
alpha or IL-1beta Quantikine ELISA kits from R&D Systems 
was employed according to the manufacturer’s instructions. 
Briefly, 50 μl of standard, control, or sample was added in 
duplicate to ELISA plates, incubated at room temperature 
for 2 hours followed by 5 washes in wash buffer. Next, 
100 μl of conjugate was added to each well, sealed, and incu­
bated at room temperature for 2 hours followed by a wash 
step. 100 μl of substrate solution was added for 30 minutes 
followed by 100 μl of stop solution. The ELISA plate was read 
at 450 nm, and concentrations (pg/ml) were determined 
using a standard curve consisting of either recombinant 
mouse TNF-alpha or IL-1beta. 
3. Results 
3.1. CXorf56 Is an ER-Associated Protein. The purpose of the 
current study was to elucidate the possible functional conse­
quences of nuclear trafficking by nApoE41-151 with our major 
hypothesis being the fragment acts as an enhancer or a 
repressor of gene transcription. In the CNS, both microglia 
and astrocytes synthesize and secrete apoE4 [13, 14]. In a 
previous study, we documented the presence of a 17 kDa 
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(green) together with DAPI (blue). The merged images indicated the strong nuclear and cytoplasmic 
presence of the amino-terminal fragment following extracellular incubation of BV2 cells. 
amino-terminal fragment of apoE4 in the nucleus of microg-
lia in human postmortem AD brain sections but found no 
evidence for this fragment in the nucleus of astrocytes [8]. 
In addition, exogenous treatment of BV2 microglia cells with 
the corresponding protein fragment (nApoE41-151) led to 
uptake and trafficking to the nucleus [8, 15]. To confirm 
these findings, BV2 cells representing microglia and U87 
cells representing astrocytes were treated with or without 
nApoE41-151 and labeled with an anti-His antibody to track 
the uptake and localization of the fragment following treat-
ment. As shown in Figure 1, although both cell lines took 
up the fragment from the surrounding media, nuclear local-
ization was only evident within the BV2 microglia cells 
(Figure 1(d)). Based on these results, all experiments were 
performed on BV2 microglia cells due to the fact that nuclear 
localization of nApoE41-151 would be necessary a priori in 
order for the fragment to regulate gene transcription directly. 
nApoE41-151 
10 𝜇m 
DAPI Merge 
10 𝜇m 10 𝜇m 
(a) (b) (c) 
5 𝜇m 
(d) 
Figure 1: Nuclear localization of an amino-terminal fragment of apoE4 is confirmed in microglia cells but not in astrocytes. (a–c) U87 cells, 
representing an astrocytic cell line, were plated on glass chamber slides in normal growth media and treated for 24 hours with the nApoE41-151 
fragment. Following treatment, cells were fixed and immunocytochemistry was carried out using an anti-His rabbit, polyclonal antibody at 
1 : 2,000, followed by the HRP-conjugated secondary antibody at 1 : 200 (see Materials and Methods for details). Under these experimental 
conditions, although there was evidence of the cytoplasmic uptake of the fragment (a), little nuclear localization of the nApoE41-151 
fragment was observed following treatment (c, merge). Scale bars represent 10 μm. (d) A representative set of images showing nuclear 
localization in the microglial cell line, BV2, following exogenous treatment with the nApoE41–151 fragment. BV2 microglial cells were 
placed on glass chamber slides in normal growth media and treated for 24 hours with the nApoE41–151 fragment. Following treatment, 
cells were fixed and immunocytochemistry was carried out as described above. Double-label immunofluorescence confocal z-stacks were 
acquired to detect nApoE41–151 
As an initial approach, experiments were undertaken 
using DNA harvested from BV2 microglia cells and chroma-
tin immunoprecipitation (ChIP-seq) analyses to determine 
what DNA sequences the nApoE41-151 fragment may be 
binding to directly. Using this approach, a DNA sequence 
pulled down by immobilized nApoE41-151 was mapped to a 
5′ region on chromosome 18 designated Gm8181 in the 
murine genome (BV2 cells are of murine origin). This DNA 
sequence was pulled down on three separate occasions 
employing chromatin immunoprecipitation. Other sequences 
that were also pulled down were too degraded to confirm 
sequence identity. Examination of this sequence revealed an 
uncharacterized gene on human chromosome X termed 
CXorf56. Although the two genes are named differently in 
the mouse and human, the proteins are virtually identical with 
there being one amino acid out of 222 that is different between 
the two species (99.5% sequence identity). Therefore, for clar­
ification purposes, we will refer to the mouse gene as the 
CXorf56 homologue and the mouse protein as CXorf56. 
Although the CXorf56 gene has recently been linked to a 
form of intellectual disability [16], the subcellular localization 
and function of the expressed protein in the CNS are cur-
rently not known. Thus, we performed confocal immunoflu­
orescence studies in microglia cells using an antibody specific 
to the mouse CXorf56 protein to determine its possible cellu­
lar localization. Perinuclear cytoplasmic labeling of this anti-
body was evident in BV2 microglia cells. Double-label 
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confocal microscopy studies ruled out a staining in mito­
chondria as evidenced by the lack of colocalization of the 
anti-CXorf56 antibody with known mitochondrial markers 
(Fig. S1). In contrast, a strong colocalization of CXorf56 with 
calnexin, a specific endoplasmic reticulum (ER), was evident 
following confocal microscopy analysis (Figures 2(a)–2(c)). 
To confirm these immunocytochemistry findings, Western 
blot analysis was performed in whole-cell BV2 extracts or 
ER-enriched fractions. ER-enriched fractions were validated 
following immunoblotting with calnexin (Figure 2(d), right 
panel). Immunoblotting with the anti-CXorf56 antibody 
revealed a specific band in the ER-enriched fraction corre­
sponding to the correct predicted molecular weight of 
CXorf56 at 34 kDa (Figure 2(d), left panel). Additional exper­
iments utilizing mouse liver microsomes that are enriched 
with ER confirmed the high expression of CXorf56 within 
the ER (Fig. S2). Taken together, these results identify 
CXorf56 as an ER-specific protein. 
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(b)(a) 
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Figure 2: Subcellular localization of the CXorf56 protein to the ER in microglial, BV2 cells. (a–c) Representative images from confocal 
immunofluorescence in BV2 cells utilizing an anti-CXorf56 antibody (a, green) and an anti-calnexin antibody, an ER-specific marker (b, 
red), with the overlap image shown in (c) (yellow). DAPI nuclear labeling in blue is shown in (c). A strong perinuclear colocalization 
between these two antibodies was evident (c). (d) Western blot analysis was carried out using BV2 whole cell lysates (left lanes) or 
enriched ER fractions (right lanes), and transferred proteins were probed with either the CXorf56 antibody (left panel, 1 : 500) or with the 
ER marker, calnexin (right panel, 1 : 1,000). The results indicated a 34 kDa immunoreactive band by the CXorf56 antibody in the ER 
fraction to which calnexin was also immunolabeled (right panel, 90 kDa band). Data are representative of three independent experiments. 
3.2. The CXorf56 Protein Is Required to Maintain Microglia 
Cells in a Quiescent Morphological Phenotype. To assess a 
possible function for CXorf56, we employed double-
stranded small interfering RNAs (siRNAs) to induce short-
term silencing of the CXorf56 gene expression. For these 
experiments, we designed three different siRNAs: a scram­
bled siRNA sequence that would serve as a negative control 
and two siRNAs (siRNA(2) and siRNA(3)) designed to spe­
cifically target CXorf56 mRNA for degradation. BV2 microg­
lia cells were treated for 5 hours with either one of these 
constructs followed by real-time quantitative PCR (qPCR) 
using SFSR11 and EHBP as internal controls for expression 
(see Materials and Methods for details). Control experi­
ments indicated that >90% of BV2 cells were successfully 
transfected following treatment of cells with siRNA con­
structs. In contrast to the negative siRNA control, treatment 
with siRNA(2) or (3) led to a 40% and 50% downregulation, 
respectively, of CXorf56 mRNA (Figure 3(a)). It is 
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noteworthy that increasing concentrations of siRNA above 
what is shown in Figure 3 did not lead to a greater knock­
down of CXorf56 mRNA. At this time, it is not known 
why we were not able to achieve a greater degree of 
knockdown but it could be related to a number of factors 
including proper cellular localization, incorrect 3D struc­
ture, or inaccessibility due to bound proteins. Verification 
of CXorf56 protein knockdown was obtained following 
Western blot analysis (Figure 3(b)). Confocal microscopy 
using anti-CXorf56 demonstrated a decrease in the stain­
ing intensity as compared to nontreated controls or BV2 
cells treated with the negative siRNA control construct 
(Figures 3(c)–3(f)). Interesting, in addition to a decrease 
in CXorf56 staining intensity, we also observed a morpho­
logical change following CXorf56 knockdown. As depicted 
in Figures 3(e) and 3(f), microglia cells became elongated 
and bipolar in appearance. 
To further characterize a potential morphological role 
for CXorf56, we carried out bright-field, phase-contrast 
microscopy with quantitative analysis using the ImageJ 
software. Visually, knockdown by either siRNA(2) or (3) 
resulted in cells extending out long pseudopods (arrowheads, 
Figure 4(d)). Cells also appeared flatter with bright, vesicular 
structures within the cytoplasm (arrow, Figure 4(d)). A 
quantitative analysis indicated a significant increase in both 
the percent of microglia with pseudopods (Figure 4(e)) as well 
as the overall length of pseudopods per cell (Figure 4(f)). 
Taken together, these data suggest that the knockdown of 
the CXorf56 protein leads to a morphological shift to an acti­
vated state that is characterized by extension of pseudopods 
as well as in increase in vacuolar appearance [17–19]. 
3.3. An Amino-Terminal Fragment of apoE4 Leads to 
Microglia Activation. Next, we sought to determine a role 
for apoE4 in activating microglia using BV2 cells as a model 
system. We recently demonstrated a key role for an amino-
terminal fragment of apoE4 1-151 (nApoE41-151) localizing 
to the nucleus of microglia in the human AD brain [8]. In 
addition, treatment of BV2 microglia cells with nApoE41­
151 leads to an uptake and trafficking of nApoE41-151 to the 
nucleus [8, 15]. We hypothesized that this fragment may be 
acting as a transcription factor changing the expression of 
proteins that may promote the inflammation associated with 
AD. To test this directly in the current study, we incubated 
BV2 microglia cells with 25 μg/ml nApoE41-151 or an equiva­
lent concentration of full-length apoE4 and assessed any 
morphological and/or functional changes that may result in 
connection with CXorf56. This concentration of nApoE41­
151 is within the range of the normal concentration of apoE 
that has been documented in the human brain (3-5 μg/ml) 
[20]. A concentration of 25 μg/ml was chosen because we 
obtained inconsistent results with lower concentrations of 
nApoE41-151, and overall, 10 μg/ml nApoE41-151 did not lead 
to a decrease in the level of the CXorf56 protein (see below). 
Treatment of BV2 microglia cells with nApoE41-151 resulted 
in a significant downregulation of the CXorf56 homologue 
mRNA (blue bar, Figure 5(a)) while full-length apoE4 had 
no significant effect (red bar, Figure 5(a)). In addition, we 
observed a 73.5% decrease in the expression of the CXorf56 
protein as demonstrated by Western blot analysis following 
incubation of BV2 cells with a 25 μg/ml nApoE4 fragment, 
while 10 μg/ml had no significant effect (Figures 5(a)–5(c)). 
Confocal immunofluorescence microscopy demonstrated a 
decrease in the staining intensity of CXorf56 following treat­
ment with nApoE41-151 (Figures 5(d) and 5(e)). Moreover, 
there was a clear shift in the morphology of cells that was 
similar to what was observed following CXorf56 knockdown 
with siRNA (arrowheads, Figure 5(e)); cells became elon­
gated and bipolar, sending out long pseudopods. The actions 
of nApoE41-151 were independent of cell toxicity and subse­
quent degradation of the CXorf56 protein as assessed by the 
release of LDH in media by BV2 microglia cells (Fig. S3). 
These data suggest that nApoE41-151 may promote a mor­
phological shift of microglia cells via downregulation of the 
CXorf56 protein. 
3.4. An Amino-Terminal Fragment of apoE4 Specifically 
Binds to the TNFα Promoter Region and Leads to Increased 
Secretion of TNFα and IL-1beta. Activated microglia express 
proinflammatory cytokines such as tumor necrosis factor 
alpha (TNFα) as well as IL-1beta, which are well-known 
signature cytokines of microglia activation. Treatment of 
BV2 microglia cells with nApoE41-151 leads to a 24.5-fold 
increase in TNFα expression (Figure 6(a)). Paralleling the 
mRNA expression, we documented a significant, 68-fold 
increase in the level of secreted TNFα protein in the media 
following treatment of BV2 microglia cells with nApoE41-151 
(Figure 6(b)). As a control, we also tested whether this was 
related directly to the apoE4 fragment by testing myoglobin 
that consists of roughly the same number of amino acids 
and molecular weight. Myoglobin consists of 153 amino 
acids and has a molecular weight of 16.7 kDa. As shown in 
Figure 6(b), exposure of BV2 cells to myoglobin at the same 
concentration as to nApoE41-151 did not lead to an increase 
in secreted TNFα (red bar, Figure 6(b)). Moreover, we 
noticed qualitatively no change in the morphology with 
myoglobin as compared to the nApoE41-151. Similar to the 
results with TNFα, we also observed a 59-fold increase in 
the secretion of IL-1beta following treatment of BV2 cells 
with nApoE41-151 (Figure 6(c)), with little effect observed 
following treatment with myoglobin. These results suggest 
a specific action of nApoE41-151 on BV2 cells versus a more 
general microglial response. 
To test whether the nApoE41-151 fragment interacts 
specifically with the TNFα DNA promoter region, gel mobil­
ity shift assays were performed. Biotinylated DNA corre­
sponding to the upstream 200 bp promoter region of TNFα 
in the mouse was incubated with nApoE41-151, and a signifi­
cant degree of DNA retardation was observed (Figure 6(d)). 
This shift was somewhat attenuated by preincubating the 
nApoE41-151 fragment with an anti-His tag antibody that 
specifically recognizes the amino-terminal fragment of 
nApoE41-151 (far right panel, Figure 6(d)). In a final set of 
experiments, we directly compared the ability of full-length 
apoE4 to bind to the TNFα promoter region. As shown in 
Figure 6(e), in contrast to the nApoE41-151 fragment, full-
length apoE4 did not lead to a mobility shift, suggesting 
that the binding of nApoE41-151 is a specific event. Taken 
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Figure 3: Confirmation of CXorf56 knockdown in BV2 microglial cells following treatment with siRNAs. (a) BV2 cells were treated for 5 
hours with a scrambled siRNA sequence (Neg. siRNA Ctl, green bar) or two designed sequences (siRNA2, blue bar or siRNA3, red bar) 
targeted to the CXorf56 open reading frame. Following treatment, total RNA was extracted and RT qPCR was performed. In contrast to 
the negative siRNA control, siRNA(2) and siRNA(3) led to a 40% and 58% downregulation, respectively, of CXorf56 mRNA. ∗ denotes 
significant difference between scrambled negative control and siRNA(2), p = 0  0003. # denotes significant difference between negative 
control and siRNA(3), p = 0  0005. (b) Western blot analysis utilizing an anti-CXorf56 antibody (1 : 500) confirmed the decreased 
expression of the CXorf56 protein following treatment of BV2 cells for 24 hrs with siRNA2 (middle lane) or siRNA3 (far right lane). Beta­
actin was employed as a loading control utilizing an anti-beta-actin antibody (1 : 50K), bottom panel. Data are representative of three 
independent experiments ± S D (c–f) Representative confocal immunofluorescence images utilizing an anti-CXorf56 antibody in BV2 
cells following treatment with siRNAs for 24 hours with nontreated cells (c), negative siRNA control (d), siRNA(2) (e), and siRNA(3) (f). 
A decrease in staining intensity with the anti-CXorf56 antibody was observed following treatment with siRNA2 (e) and to a lesser extent 
with siRNA3 (f). Note also the apparent change in morphology following treatment with extended, bipolar pseudopods in (e) and (f). 
8 Oxidative Medicine and Cellular Longevity 
together, these results suggest an activation of microglia by 
nApoE41-151 that occurs at least in part by changes in gene 
expression of CXorf56 and TNFα. 
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Figure 4: Downregulation of the CXorf56 protein leads to morphological changes in BV2 microglia cells. (a–d) BV2 cells were untreated (a) 
or treated for 5 hours with scrambled negative control siRNA (b), siRNA2 (c), or siRNA3 targeting the open reading frame CXorf56 (d). 
Following treatment, bright-field, phase-contrast images were captured. In contrast to untreated or cells treated with the siRNA negative 
control, cells treated with targeted siRNAs led to changes in morphology from round, compact cells to cells that were flattened and 
extended long pseudopods (arrowheads, c and d) and or were highly vacuolized (arrows, c and d). Scale bars represent 10 μm. (e, f) 
Quantification using the ImageJ software showing percent of cells with pseudopods was significantly increased following treatment with 
either siRNA2 or 3 (e, blue and red bars) as was the length of pseudopods per cell (f, blue and red bars). In (e), ∗ denotes significant 
difference between scrambled siRNA negative control (orange bar) and siRNA(2) (blue bar), p = 0  002; # denotes significant difference 
between scrambled siRNA negative control (orange bar) and siRNA(3) (red bar), p = 0  009. In (f), ∗  denotes significant difference between 
scrambled siRNA negative control (orange bar) and siRNA(2) (blue bar), p = 0  002; # denotes significant difference between scrambled 
siRNA negative control (orange bar) and siRNA(3) (red bar), p = 0  009. Data in (e) and (f) are representative of 4 independent 
experiments ± S E M 
4. Discussion 
A central question in AD is determining how harboring the 
APOE4 allele translates molecularly into an increased risk 
for dementia. One possibility is the apoE4 protein may lead 
to enhanced inflammation that has long been documented 
in the AD [7, 21–25]. Emerging data suggests that apoE4 
may promote pathology associated with AD through a 
gene-regulating mechanism. Thus, data from our lab and 
others have documented a nuclear localization for apoE4 that 
may lead to gene expression changes [15]. Recently, we dem­
onstrated nuclear localization of an amino-terminal frag­
ment of apoE4 nApoE41-151 within microglia of the human 
AD brain and within BV2 microglia cells [8, 15]. BV2 cells 
are a well-characterized, extensively employed model system 
for microglia. Studies have demonstrated that BV2 cells are a 
valid substitute for primary microglia in many experimental 
settings, including complex cell-cell interaction studies [26]. 
9 Oxidative Medicine and Cellular Longevity 
For example, this study showed that in response to LPS, 90% 
of genes induced by the BV2 cells were also induced by pri­
mary microglia. In the current study, employing BV2 
microglia cells as a model system, we tested the hypothesis 
that the link between harboring the APOE4 allele and inflam­
mation in AD may be activation of microglia by altering the 
expression of specific proinflammatory genes. 
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Figure 5: Treatment of BV2 microglial cells with an amino-terminal fragment of apoE4 leads to the downregulation of CXorf56. (a) BV2 cells 
were treated for 5 hours with 25 μg/mg nApoE41-151 (blue bar) or with an equivalent concentration of full-length apoE4 (red bar). Following 
treatment, RNA was extracted and RT qPCR was performed. Data indicated a significant decrease in the expression of the CXorf56 
homologue following treatment, p = 0  0002, while full-length apoE4 had no significant effect. (b, c) Western blot analysis utilizing an anti­
CXorf56 antibody (1 : 500) confirmed the decreased expression of the CXorf56 protein following treatment of BV2 cells for 24 hrs with 
25 μg/ml nApoE41-151. Beta-actin was employed as a loading control utilizing an anti-beta-actin antibody (1 : 50K), bottom panel. (c) 
Quantitative densitometry analysis of 3 independent experiments showing an overall 74% decrease in the expression of CXorf56 protein 
following treatment (∗ denotes p = 5  76 × 10−7). Data are representative of 3 independent experiments ± S D (d, e) BV2 cells were left 
untreated (d) or treated for 24 hours with nApoE41-151 and stained with the CXorf56 antibody. Following treatment, there was a decrease 
in the staining intensity as well as a morphological shift to bipolar, extended pseudopods (arrowheads, e). 
In the present study, we identified a novel protein, 
CXorf56, as a potential link between apoE4 and microglia 
activation. Very little is known about the CXorf56 gene or 
the protein other than it has been recently linked to an 
inherited form of intellectual disability [16]. Our results 
demonstrate that the CXorf56 protein resides specifically 
within the ER of BV2 microglia and in liver microsomes. 
In addition, knockdown of CXorf56 expression led to a dis­
tinct morphological shift of BV2 microglia cells to an acti­
vated phenotype. Our data suggest that CXorf56 is required 
to maintain microglia cells in a round, compact morphology 
with little ramification. How downregulation of the CXorf56 
protein leads to a morphological shift is not known, but it 
may occur through the ER stress pathway. Thus, several 
studies have linked CNS inflammation mediated in part by 
the activation of microglia through the ER stress pathway 
[27–30]. The ER stress response constitutes a cellular pro­
cess that is stimulated by a variety of conditions that disturb 
the normal folding of proteins in the ER. Eukaryotic cells 
have developed an adaptive mechanism referred to as the 
unfolded protein response (UPR), which is aimed at clearing 
unfolded proteins and restoring ER homeostasis [31]. It may 
be that the function of CXorf56 is somehow delegated to 
maintaining the functioning of UPR, although future studies 
will be needed to assess this hypothesis. 
A key outcome of the present study was identifying a 
novel pathway by which an amino-terminal fragment of 
apoE4 (nApoE41-151) may lead to microglia activation. 
Although it is well established that harboring the APOE4 
allele enhances dementia risk, the molecular mechanisms 
underlying this risk has not been well established. Recent 
studies from our lab have supported a novel pathway for 
nApoE41-151 whereby localization within the nucleus may 
lead to gene expression changes [8, 15]. In the present 
study, we now demonstrate that nApoE41-151 leads to the 
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Figure 6: Treatment of BV2 microglial cells with an amino-terminal fragment of apoE4 leads to the upregulation of inflammatory cytokines. 
(a) BV2 cells were left untreated (control, green bar) or treated for 5 hours with 25 μg/ml nApoE41-151 (blue bar), and RNA was extracted. RT­
PCR analysis indicated a 24.5-fold increase in the expression of inflammatory cytokine, TNFα. ∗ denotes significant difference, p = 0  016. (b) 
Secreted TNFα levels are significantly elevated following the treatment of BV2 cells with nApoE41-151 (blue bar) as compared to untreated 
controls (green bar) or an unrelated protein, myoglobin, of similar size and weight to nApoE41-151 (red bar, middle). Data are 
representative of 3 independent experiments ± S E M ∗ denotes significant difference, p = 3  8 × 10−8 between control and nApoE41-151, 
while # represents significant difference, p = 0  00075 between myoglobin and nApoE41-151. (c) Secreted IL-1beta levels are significantly 
elevated following the treatment of BV2 cells with nApoE41-151 (blue bar) as compared to untreated controls (green bar) or an unrelated 
protein, myoglobin, of similar size and weight to nApoE41-151 (red bar, middle). Data are representative of 3 independent experiments ± S 
E M ∗ denotes significant difference, p = 0  013. (d, e) DNA gel mobility shift assay was used to determine a specific interaction of 
nApoE41-151 with the 200 bp promoter region of mouse TNFα. (d) Biotinylated end-labeled DNA corresponding to the mouse TNFα 
promoter region was incubated alone or in addition of 25 μg/ml of nApoE41-151. There was an upward shift in the DNA band indicating a 
binding of the fragment to DNA. The last lane was performed similarly except that the nApoE41-151 fragment was preincubated first with 
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downregulation of the murine CXorf56 homologue mRNA 
and protein resulting in a morphological shift that mir­
rored the downregulation of CXorf56 by siRNA constructs. 
Additionally, we show that treatment of BV2 microglia cells 
with nApoE51-151 led to a 24.5-fold increase in mRNA TNFα 
expression, a potent proinflammatory cytokine. A corre­
sponding 68-fold increase of the secreted TNFα protein was 
detected in the media following ELISA analysis. We also 
observed a parallel 59-fold increase in the secretion of the 
IL-1beta cytokine. Finally, we demonstrate a specific interac­
tion of the nApoE41-151 fragment with the mouse TNFα pro­
moter region. In contrast, no specific interaction of full-
length apoE4 with this promoter region was observed. In 
pathological conditions, microglia produce large amounts 
of TNFα that serves as an important component of neuroin­
flammatory response that is associated with several neuro­
logical disorders including AD [32–34]. In addition, the 
secretion of TNFα and IL-1beta serves as a classic signature 
for microglia activation as has been observed in AD [35]. It 
is noteworthy that in our studies we treated cells with a 
concentration of 25 μg/ml of nApoE41-151. In the previous 
study, the levels of apoE4 in the cerebral spinal fluid (CSF) 
were measured as being approximately 3-5 μg/ml [20]. Also, 
we observed inconsistent effects of 10 μg/ml nApoE41-151 on 
the downregulation of the CXorf56 protein, and overall, this 
concentration of nApoE41-151 had no statistical effect on the 
downregulation of the CXorf56 protein. Although the con­
centration of nApoE41-151 used was within an order of mag­
nitude, future studies should examine whether lower 
concentrations of the nApoE41-151 fragment lead to signifi­
cant changes in cytokine levels in order to put our current 
findings in a more physiological context. 
We also examined whether downregulation of the 
CXorf56 protein led to changes in TNFα levels similar to 
what was observed for the nApoE4 fragment. Following 
treatment of cells with siRNA to CXorf56, we actually 
observed a slight decrease in the TNFα mRNA levels (82% 
of control levels). These results suggest that the CXorf56­
associated changes in morphology are distinct from the 
upregulation of TNFα and that these two separate phenom­
ena are associated with nApoE41-151 fragment exposure but 
are not necessarily directly related. 
5. Conclusions 
Collectively, these data suggest that apoE4 may promote the 
activation of microglia by a gene-regulatory mechanism 
involving a newly identified protein, CXorf56 as well as 
TNFα. These results suggest a novel role for apoE4 and pro­
vide a possible link to the inheritance of this allele to inflam­
mation associated with AD. Future studies should be directed 
towards replicating these findings in primary microglia cul­
tures or in induced pluripotent stem cells. 
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Supplementary Materials 
Fig. S1: confocal labeling of two different markers in BV2 
microglial cells. The green image in (A) is showing the use 
of the cytochrome C antibody, the red label is showing the 
use of the CXorf56 antibody (B), and (C) is showing the over­
lap image. Fig. S2: representative Western blot analysis using 
the CXorf56 antibody in increasing amounts of liver micro­
somes. The data show the presence of a single 34 kDA band 
corresponding to the molecular weight of native CXorf56. 
Fig. S3: quantitative analysis of BV2 microglia toxicity by 
measuring the release of LDH in the media. The data show 
untreated, control cells (blue bar) and the following treat­
ment with the apoE4 1-151 amino-terminal fragment 
(orange bar). There was no significant difference in cytotox­
icity following treatment. (Supplementary Materials) 
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